

References

- Billiau, A. (1996). Interferon- γ : biology and role in pathogenesis. *Advances in Immunology*, 62, 61-130.
- Gani, Z. (n.d.). Complement system. Bitesized Immunology. British Society for Immunology. Retrieved November 13, 2024, from <https://www.immunology.org/public-information/bitesized-immunology/systems-processes/complement-system>
- Chapman, T.W., Olveda, G.E., Bame, X. et al. (2023). Oligodendrocyte death initiates synchronous remyelination to restore cortical myelin patterns in mice. *Nature Neuroscience*, 26, 555–569. <https://doi.org/10.1038/s41593-023-01271-1>
- Ernst, A., Stolzing, A., Sandig, G. et al.. (2004). Antioxidants effectively prevent oxidation-induced protein damage in OLN 93 cells. *Archives of Biochemistry and Biophysics*, 421(1), 54–60. <https://doi.org/10.1016/j.abb.2003.10.008>
- Falcão, A. M., van Bruggen, D., Marques, S., et al. (2018). Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. *Nature Medicine*, 24(12), 1837-1844.
- Glass, W. G., Hickey, M. J., Hardison, J. L. et al. (2004). Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. *Journal of Immunology*, 172(7), 4018-4025.
- Guerrero, B. L., & Sicotte, N. L. (2020). Microglia in multiple sclerosis: Friend or foe? *Frontiers in Immunology*, 11, Article 374. <https://doi.org/10.3389/fimmu.2020.00374>

Halkjær, L., Troldborg, A., Pedersen, H., et al. (2020). Complement receptor 2-based immunoassay measuring activation of the complement system at C3-level in plasma samples from mice and humans. *Frontiers in Immunology*, 11, 774.

<https://doi.org/10.3389/fimmu.2020.00774>

Hauser, S. L., & Cree, B. A. C. (2021). Treatment of Multiple Sclerosis: A Review.

American Journal of Medicine, 133(12):1380–1390.e2. doi:
[10.1016/j.amjmed.2020.05.049](https://doi.org/10.1016/j.amjmed.2020.05.049).

Lloyd, A. F., & Miron, V. E. (2019). The pro-remyelination properties of microglia in the central nervous system. *Nature Reviews Neurology*, 15, 447–458.

<https://doi.org/10.1038/s41582-019-0184-2>

Mansilla, M. J., Press-Rodriguez, S., Teniente-Serra, A. et al. (2021). Paving the way towards an effective treatment for multiple sclerosis: Advances in cell therapy. *Cellular and Molecular Immunology*, 18(6):1353–1374. doi: [10.1038/s41423-020-00618-z](https://doi.org/10.1038/s41423-020-00618-z)

Michailidou, I., Naessens, D. M., Hametner, S. et al. (2017). Complement C3 on microglial clusters in multiple sclerosis occur in chronic but not acute disease: Implication for disease pathogenesis. *Glia*, 65(2), 264–277. <https://doi.org/10.1002/glia.23090>

Peschl, P., Bradl, M., Höftberger, R. et al. (2017). Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases. *Frontiers in Immunology*, 8, 529.

Rahimian, R., Perlman, K., Canonne, C. et al. (2022). Targeting microglia–oligodendrocyte crosstalk in neurodegenerative and psychiatric disorders. *Drug Discovery Today*, 27(9), 2562–2573. <https://doi.org/10.1016/j.drudis.2022.06.015>

Rawji, K. S., & Yong, V. W. (2013). The benefits and detriments of macrophages/microglia in

models of multiple sclerosis. *Clinical & Developmental Immunology*, 2013, 948976.

<https://doi.org/10.1155/2013/948976>

Reynolds, A., Laurie, C., Mosley, R. L. et al. (2007). Oxidative stress and the pathogenesis of neurodegenerative disorders. *International Review of Neurobiology*, 82, 297–325. [https://doi.org/10.1016/S0074-7742\(07\)82016-2](https://doi.org/10.1016/S0074-7742(07)82016-2)

Traka, M., Podojil, J. R., McCarthy, D. P. et al. (2016). Oligodendrocyte death results in immune-mediated CNS demyelination. *Nature Neuroscience*, 19(1), 65-74.

Takeuchi, H. (2010). Neurotoxicity by microglia: Mechanisms and potential therapeutic strategy. *Clinical and Experimental Neuroimmunology*, 1(1), 12–21.

<https://doi.org/10.1111/j.1759-1961.2009.00001.x>

Wee Yong, V. (2022). Microglia in multiple sclerosis: Protectors turn destroyers. *Neuron*, 110(21), 3534–3548. <https://doi.org/10.1016/j.neuron.2022.06.023>